Ferroptosis in strokes, page-3

larrybird, yes, your question is very valid. We are not told anything and so we do not know anything if something is already happening. But most likely the reason nothing is happening in these possible other indications is that ATH434 is not yet on the market. When ATH434 gets approved ( still ???) by FDA in MSA, it is much easier to start to study other possible indications. Most of these other indications need also phase 3 studies and they are at this time too expensive for ATHE. This is the very reason 434 is tested in this orphan indication MSA needing only positive results in ph 2 to get approval.
PBT2 could bring more money when the "Big Deal" will be done ( today 6 months ago the deal with Queensland was told). Even in this case, it can be best to wait for the results of the ph 2 in MSA. The priorities seem to be to see the effect of 434 in PD and perhaps in AD and to get these ph3 studies done. However, with clever consideration, it could well be possible to find collaborators in these other indications. However, not in the way Queensland did. There is so much to do before starting any ph 2 human studies in these other indications. PBT2 royalties can give possibilities for these preclinical studies.